Results 231 to 240 of about 209,848 (307)

Exploiting ALK inhibition in anaplastic large cell lymphoma: Biological rationale and therapeutic integration

open access: yesBritish Journal of Haematology, EarlyView.
Summary Mature T‐cell lymphomas comprise a heterogeneous group of aggressive non‐Hodgkin lymphomas with limited therapeutic options in the relapsed or refractory setting. Among them, anaplastic lymphoma kinase (ALK)‐positive anaplastic large cell lymphoma (ALCL) represents a biologically distinct subtype driven by constitutive activation of ALK fusion ...
Santino Caserta   +13 more
wiley   +1 more source

Novel <i>SZT2::MAST2</i> Fusion Detected in Salivary Duct Carcinoma. [PDF]

open access: yesCase Rep Pathol
Bedeir A   +4 more
europepmc   +1 more source

Targeting BRAF in cancers - from molecular diagnostics to personalized therapy. [PDF]

open access: yesBioTechnologia (Pozn)
Pyc Z   +4 more
europepmc   +1 more source

Non‐canonical PKG1 regulation in cardiovascular health and disease

open access: yesBritish Journal of Pharmacology, EarlyView.
It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley   +1 more source

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy